Latest Move Marks Continued Expansion of European Footprint in Growing Medical Cannabis Market
LONDON, August 10, 2022 – Curaleaf International (the “Company”) part of Curaleaf Holdings (CNSX:CURA), Europe’s largest vertically integrated cannabis company, is pleased to announce the successful registration of the Company’s cannabis based medicines as extract in Poland, with local partner CanPoland S.A.. Poland is one of the largest medical cannabis markets in Europe by patient population1, with a market size expected to be worth at least €2 billion by 20282.
The licensed product is part of the Company’s product range being manufactured to meet the growing demand for high quality medical cannabis products across Europe. The licensed product, 100%-European sourced from plant to manufacture, is part of Curaleaf International’s proprietary product range that has now launched in five key European markets, including the UK and Germany.
In addition to the Polish licence, Curaleaf International has previously announced registrations of products in Malta as well as being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient (“API”) in Italy. This positive news, taken together with the opening of the Swiss medical cannabis market and Curaleaf International’s renewing of its GDP licence in Switzerland is another example of where the Company is ideally positioned to capitalise on positive market movements across Europe.
Commenting on this landmark registration, Curaleaf International President Miles Worne said: “This licence in Poland is another sign of Curaleaf International’s strong momentum in Europe. The medical cannabis market in Europe continues to expand rapidly, as regulation opens up and access for patients improves. Since the legalisation of medical cannabis in 2017, Poland has become one of the largest European importers of dried flower and is an excellent addition to Curaleaf International’s expansion, given its fast-growing patient numbers and significant addressable market. Curaleaf International is driving growth in existing key markets, with the UK in particular witnessing a huge increase in patient numbers, whilst continuing to drive expansion into new markets across Europe.”